Divya Chaudhary

Pharmaceutical R&D and Commercial Strategy

 links
 https://www.linkedin.com/in/divya-chaudhary-7584579
 https://twitter.com/divya_divyach
https://www.researchgate.net/profile/Divya_Chaudhary3


Divya Chaudhary has been working in the pharmaceutical and biotechnology industry in drug discovery and development of small molecules and biologics for autoimmune diseases and oncology at Wyeth, Pfizer, and Nimbus Discovery. She received her Ph.D. from University of Alabama at Birmingham at the Comprehensive Cancer Center, working on regulation of oncogene expression, and did postdoctoral fellowships at University of Michigan and Genentech in molecular oncology and signal transduction.

Summary

Created value in pharmaceutical R&D organizations in small molecule and biologics drug discovery and development. Strong experience in strategic thinking and innovation, communication and diligence, and effective management of projects with diverse functional teams.

 Effectivey managed external partners and client relations
 Mentored staff as they enter and grow in organizations
 Unique combination of a deep scientific and a strategy consulting experience

Disease areas experience in inflammation, autoimmune diseases, respiratory diseases, and immuno-oncology

Specialized in commercialization and operations strategy in life sciences, pharmacology, biochemistry, cell biology, CRO and supply chain, and program and alliance management

Experience

Consultant

IMS Health

2016 – Present (less than a year)

Managed Markets Strategy for Commercialization of Bio-Pharmaceutical Products
Conducted subnational market analysis and created Tableau dashboard tools for a newly launched therapeutic to help define local market strategies

Life Science Consultant

Putnam Associates

September 2014 – December 2015 (1 year 4 months)

 Conducted primary research with physicians, academics, and key opinion leaders for development insights and commercial assessments for multiple assets
 Analyzed physician and patient data to understand segmentation/ positioning and building patient journey and treatment flow models
 Refined a revenue model by performing sensitivity analysis, for the purpose of projecting revenue scenarios
 Conducted due diligence for private equity client evaluating a medium sized pharmaceutical company’s assets
 Developed product positioning strategies for cell immunotherapy product in hematology
 Assessed global opportunities in vaccines; conducted research for HEOR analysis data inputs for the purpose of asset prioritization

Head of Pharmacology

Nimbus Discovery

2011 – 2014 (3 years)

Led preclinical discovery in a virtual CRO outsourced model, contributing to successful series B and program transaction
 Contributed to the selection of IRAK4 inhibitor development candidates resulting in program partnering with Genentech
 Communicated lead candidate profiles and timelines for board meetings and external discussions, and for diligence discussions and evaluation
 Initiated and fast tracked the oncology project strategy with staff embedded at a CRO

Managed the early efforts to initate the ACC inhibitor evaluation in tumor cell lines
 Developed the preclinical markers approach working with a CRO to contribute to the program's oncology strategy

Advanced critical business development objectives in the areas of cancer and autoimmune disease
 Evaluated and critiqued multiple target ideas; initiated and implemented two programs
 Proposed, planned, and led TYK2 inhibitor lead optimization biology effort

Writer

Biopharmaceutical R&D

June 2011 – November 2011 (6 months)

Performed writing work for bio-pharmaceutical company

Consultant

Nimbus Discovery

June 2011 – November 2011 (6 months)

Project management for IRAK4 inhibitor and ACC inhibitor programs lead discovery efforts, with contract research organization, for both fee for service and full time equivalent resourced projects

Senior Principal Scientist

Pfizer Pharmaceuticals

2009 – 2011 (2 years)

Managed the preclinical, biomarker, and pharmacology strategy for four autoimmune disease programs (small molecule and biologics)

Scientist

Wyeth Research

1998 – 2009 (11 years)

Managed and led two biologics programs and one small molecule program

Postdoctoral Fellow

Genentech

1997 – 1998 (1 year)

Postdoctoral Research

University of Michigan

1997 – 1998 (1 year)

Education

Northeastern University

MBA

2013

Activities and Societies: Beta gamma sigma

Indian Institute of Technology, Roorkee

M.Sc., BioSciences and Biotechnology

Graduated top of the class with a gold medal award

Activities and Societies: RUSA Senator

Meerut University, Maharaj Singh College in Saharanpur

B.Sc., Biology

University of Alabama at Birmingham - School of Medicine

Ph.D., Biochemistry and Molecular Genetics

Recent Advances in the Discovery of Small Molecule Inhibitors of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) as a Therapeutic Target for Inflammation and Oncology Disorders

Miniperspective

Divya Chaudhary†, Shaughnessy Robinson‡, and Donna L. Romero*†

† Nimbus Discovery, 25 First Street, Suite 404, Cambridge, Massachusetts 02141, United States

‡ Schrödinger Inc., 120 West Forty-Fifth Street, New York, New York 10036, United States

J. Med. Chem., 2015, 58 (1), pp 96–110

DOI: 10.1021/jm5016044

http://pubs.acs.org/doi/full/10.1021/jm5016044